Antifungal Clotrimazole 1 percent is scheduled formulation under DPCO 2013: NPPA
New Delhi: In line with the Drug (Prices Control) Order, 2013, the National Pharmaceutical Pricing Authority (NPPA) Committee, at its recent Multidisciplinary Committee meeting, has clarified that Clotrimazole 1% mouth paint is a scheduled formulation.
This came during the 36th meeting of the Multidisciplinary Committee of Experts held on 11.10.2021 where the issue of whether the Clotrimazole 1 percent mouth paint would fall under the Scheduled formulation was discussed.
Clotrimazole is a synthetic, imidazole derivate with broad-spectrum, antifungal activity. It is used primarily in the treatment of skin, oral and vaginal candida infections. Clotrimazole inhibits biosynthesis of sterols, particularly ergosterol, an essential component of the fungal cell membrane, thereby damaging and affecting the permeability of the cell membrane. This results in leakage and loss of essential intracellular compounds, and eventually causes cell lysis.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.